Who can have enzalutamide?
Enzalutamide is suitable for men with advanced prostate cancer that has stopped responding to other hormone therapy and chemotherapy treatments.
The National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) have approved enzalutamide for men who have already had the chemotherapy drug docetaxel. This means enzalutamide should be available for these men on the NHS.
But if you've already had abiraterone as well as chemotherapy, you may not be able to have enzalutamide.
- In England, you won’t be able to have enzalutamide if you’ve already had abiraterone – unless you had to stop taking abiraterone within three months because of severe side effects or because your cancer continued to grow.
- In Scotland, the SMC has approved the use of enzalutamide for men who have already had abiraterone – but not all hospitals are giving it to these men, as they don’t have to follow the SMC guidance.
- In Wales and Northern Ireland, enzalutamide may not be available for men who have already had abiraterone.
Early research has shown that enzalutamide may only have a small effect in men who have previously had abiraterone. But we need more research into this.
Ask your doctor if it’s better to have abiraterone or enzalutamide as the next treatment after chemotherapy. Speak to your doctor or nurse about whether enzalutamide is suitable for you. You can also talk things through with our Specialist Nurses.
Read more about getting new treatments.
Enzalutamide is also suitable for men who have stopped responding to hormone therapy but haven’t yet had chemotherapy.
If you live in England, Wales, Scotland or Northern Ireland, you should be able to have enzalutamide before chemotherapy.